Myofilament Protein Gene Mutation Screening and Outcome of Patients With Hypertrophic Cardiomyopathy

Olivotto, Iacopo; Girolami, Francesca; Ackerman, Michael J.; Nistri, Stefano; Bos, J. Martijn; Zachara, Elisabetta; Ommen, Steve R.; Theis, Jeanne L.; Vaubel, Rachael A.; Re, Federica; Armento, Corinna; Poggesi, Corrado; Torricelli, Francesca; Cecchi, Franco
June 2008
Mayo Clinic Proceedings;Jun2008, Vol. 83 Issue 6, p630
Academic Journal
OBJECTIVE: To determine the influence of a positive genetic test for hypertrophic cardiomyopathy (HCM) on clinical outcome. PATIENTS AND METHODS: A cohort of 203 unrelated patients with HCM (mean ± SD age, 50±18 years) was enrolled from January 1, 2002, through December 31, 2003. They were followed up for a mean ± SD time of 4.0±1.7 years after genetic testing of the 8 HCM-susceptibility genes that encode key sarcomeric/myofilament proteins. The clinical phenotype of those with a positive genetic test (myofilament-positive HCM) was compared with those with a negative genetic test (myofilament-negative HCM). RESULTS: In this cohort of 203 patients, 87 mutations were identified in 126 patients (myofilament-positive HCM, 62%); the remaining 77 patients (38%) were myofilament-negative. Despite similar baseline features, patients with myofilament-positive HCM showed increased risk of the combined end points of cardiovascular death, nonfatal stroke, or progression to New York Heart Association class III or IV compared with the patients with myofilament-negative HCM (25% vs 7%, respectively; independent hazard ratio, 4.27; P=.008). These end points occurred at any age among patients with myofilament-positive HCM (range, 14-86 years), but only in those aged 65 years and older among patients with myofilament-negative HCM. Moreover, patients with myofilament-positive HCM showed greater probability of severe left ventricular systolic and diastolic dysfunction, defined as an ejection fraction of less than 50% and a restrictive filling pattern (P=.02 and P<.02, respectively, vs myofilament-negative HCM). CONCLUSION: Screening for sarcomere protein gene mutations in HCM identifies a broad subgroup of patients with increased propensity toward long-term impairment of left ventricular function and adverse outcome, irrespective of the myofilament (thick, intermediate, or thin) involved.


Related Articles

  • Identification of Myofilament Mutations: Its Role in the Diagnosis and Management of Hypertrophic Cardiomyopathy. Dandona, Sonny; Roberts, Robert // Mayo Clinic Proceedings;Jun2008, Vol. 83 Issue 6, p626 

    The article presents the authors' perspective on a study concerning the identification of myofilament mutations and its role in the diagnosis and management of hypertrophic cardiomyopathy (HCM), which is published within the issue. They remark that the observation of the study should be...

  • Echocardiography-Guided Genetic Testing in Hypertrophic Cardiomyopathy: Septal Morphological Features Predict the Presence of Myofilament Mutations. Binder, Josepha; Ommen, Steve R.; Gersh, Bernard J.; Van Driest, Sara L.; Tajik, A. Jamil; Nishimura, Rick A.; Ackerman, Michael J. // Mayo Clinic Proceedings;Apr2006, Vol. 81 Issue 4, p459 

    OBJECTIVE: To examine the relationship among age, septal morphological subtype, and presence of hypertrophic cardiomyopathy (HCM)-associated myofilament mutations. PATIENTS AND METHODS: Comprehensive mutation analysis of the 8 HCM susceptibility genes that encode the myofilaments of the cardiac...

  • Cardiac myosin binding protein-C: a novel sarcomeric target for gene therapy. Mamidi, Ranganath; Li, Jiayang; Gresham, Kenneth; Stelzer, Julian // Pflugers Archiv European Journal of Physiology;Feb2014, Vol. 466 Issue 2, p225 

    Through its ability to interact with both the thick and thin filament proteins within the sarcomere, cardiac myosin binding protein-C (cMyBP-C) regulates the contractile properties of the myocardium. The central regulatory role of cMyBP-C in heart function is emphasized by the fact that a large...

  • Rapid molecular genetic diagnosis of hypertrophic cardiomyopathy by semiconductor sequencing. Zongzhe Li; Jin Huang; Jinzhao Zhao; Chen Chen; Hong Wang; Hu Ding; Dao Wu Wang; Dao Wen Wang // Journal of Translational Medicine;2014, Vol. 12 Issue 1, p1 

    Background Rapidly determining the complex genetic basis of Hypertrophic cardiomyopathy (HCM) is vital to better understanding and optimally managing this common polygenetic cardiovascular disease. Methods A rapid custom Ion-amplicon-resequencing assay, covering 30 commonly affected genes of...

  • Adiponectin-mediated modulation of hypertrophic signals in the heart. Shibata, Rei; Ouchi, Noriyuki; Ito, Masahiro; Kihara, Shinji; Shiojima, Ichiro; Pimentel, David R; Kumada, Masahiro; Sato, Kaori; Schiekofer, Stephan; Ohashi, Koji; Funahashi, Tohru; Colucci, Wilson S; Walsh, Kenneth // Nature Medicine;Dec2004, Vol. 10 Issue 12, p1384 

    Patients with diabetes and other obesity-linked conditions have increased susceptibility to cardiovascular disorders. The adipocytokine adiponectin is decreased in patients with obesity-linked diseases. Here, we found that pressure overload in adiponectin-deficient mice resulted in enhanced...

  • IMAGES IN CARDIOLOGY. Byrne, J.; Giles, J.; Walker, D. // Heart;Dec2005, Vol. 91 Issue 12, p1522 

    The article presents a case study of mid cavity hypertrophic cardiomyopathy. The patient was a 62-year old woman presented with recurrent episodes of amarosis fugax and headache. She had a past medical history of well controlled essential hypertension, and had been treated for pulmonary...

  • Expression of tropomyosin-κ induces dilated cardiomyopathy and depresses cardiac myofilament tension by mechanisms involving cross-bridge dependent activation and altered tropomyosin phosphorylation. Karam, Chehade N.; Warren, Chad M.; Rajan, Sudarsan; De Tombe, Pieter P.; Wieczorek, David F.; Solaro, R. John // Journal of Muscle Research & Cell Motility;Mar2011, Vol. 31 Issue 5/6, p315 

    Tropomyosin-kappa (TPM1-κ) is a newly discovered tropomyosin (TM) isoform that is exclusively expressed in the human heart and generated by an alternative splicing of the α-TM gene. We reported that TPM1-κ expression was increased in the hearts of patients with chronic dilated...

  • A human MYBPC3 mutation appearing about 10 centuries ago results in a hypertrophic cardiomyopathy with delayed onset, moderate evolution but with a risk of sudden death. Teirlinck, Carolien H.; Senni, Fa‹za; El Malti, Rajae; Majoor-Krakauer, Danielle; Fellmann, Florence; Millat, Gilles; Andr‚-Fou‰t, Xavier; Pernot, Fran‡ois; Stumpf, Micha‰l; Boutarin, Jean; Bouvagnet, Patrice // BMC Medical Genetics;2012, Vol. 13 Issue 1, p105 

    Background: Hypertrophic Cardiomyopathy (HCM) is a genetically heterogeneous disease. One specific mutation in the MYBPC3 gene is highly prevalent in center east of France giving an opportunity to define the clinical profile of this specific mutation. Methods: HCM probands were screened for...

  • Cardiomyopathy update: patients can expect to live longer and fuller lives. Hall, Robert // British Journal of Cardiac Nursing;May2015, Vol. 10 Issue 5, p215 

    The article offers information on the conferences to be held by Cardiomyopathy UK in 2015 in London, England which include the hypertrophic cardiomyopathy (HCM) conference on May 29 and the cardiomyopathy and pregnancy conference on June 12.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics